Aarhus University Seal / Aarhus Universitets segl

Claus Oxvig

PAPP-A and the IGF system in atherosclerosis: what's up, what's down?

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

PAPP-A and the IGF system in atherosclerosis : what's up, what's down? / Steffensen, Lasse B.; Conover, Cheryl A.; Oxvig, Claus.

In: American journal of physiology. Heart and circulatory physiology, Vol. 317, No. 5, 11.2019, p. H1039-H1049.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Steffensen, LB, Conover, CA & Oxvig, C 2019, 'PAPP-A and the IGF system in atherosclerosis: what's up, what's down?', American journal of physiology. Heart and circulatory physiology, vol. 317, no. 5, pp. H1039-H1049. https://doi.org/10.1152/ajpheart.00395.2019

APA

Steffensen, L. B., Conover, C. A., & Oxvig, C. (2019). PAPP-A and the IGF system in atherosclerosis: what's up, what's down? American journal of physiology. Heart and circulatory physiology, 317(5), H1039-H1049. https://doi.org/10.1152/ajpheart.00395.2019

CBE

Steffensen LB, Conover CA, Oxvig C. 2019. PAPP-A and the IGF system in atherosclerosis: what's up, what's down?. American journal of physiology. Heart and circulatory physiology. 317(5):H1039-H1049. https://doi.org/10.1152/ajpheart.00395.2019

MLA

Steffensen, Lasse B., Cheryl A. Conover, and Claus Oxvig. "PAPP-A and the IGF system in atherosclerosis: what's up, what's down?". American journal of physiology. Heart and circulatory physiology. 2019, 317(5). H1039-H1049. https://doi.org/10.1152/ajpheart.00395.2019

Vancouver

Steffensen LB, Conover CA, Oxvig C. PAPP-A and the IGF system in atherosclerosis: what's up, what's down? American journal of physiology. Heart and circulatory physiology. 2019 Nov;317(5):H1039-H1049. https://doi.org/10.1152/ajpheart.00395.2019

Author

Steffensen, Lasse B. ; Conover, Cheryl A. ; Oxvig, Claus. / PAPP-A and the IGF system in atherosclerosis : what's up, what's down?. In: American journal of physiology. Heart and circulatory physiology. 2019 ; Vol. 317, No. 5. pp. H1039-H1049.

Bibtex

@article{5dc6239e2e02403abe39a11d3a324381,
title = "PAPP-A and the IGF system in atherosclerosis: what's up, what's down?",
abstract = "Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.",
keywords = "atherosclerosis, IGF system, mouse models, PAPP-A",
author = "Steffensen, {Lasse B.} and Conover, {Cheryl A.} and Claus Oxvig",
year = "2019",
month = nov,
doi = "10.1152/ajpheart.00395.2019",
language = "English",
volume = "317",
pages = "H1039--H1049",
journal = "American Journal of Physiology: Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

RIS

TY - JOUR

T1 - PAPP-A and the IGF system in atherosclerosis

T2 - what's up, what's down?

AU - Steffensen, Lasse B.

AU - Conover, Cheryl A.

AU - Oxvig, Claus

PY - 2019/11

Y1 - 2019/11

N2 - Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.

AB - Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.

KW - atherosclerosis

KW - IGF system

KW - mouse models

KW - PAPP-A

UR - http://www.scopus.com/inward/record.url?scp=85074118307&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00395.2019

DO - 10.1152/ajpheart.00395.2019

M3 - Journal article

C2 - 31518159

AN - SCOPUS:85074118307

VL - 317

SP - H1039-H1049

JO - American Journal of Physiology: Heart and Circulatory Physiology

JF - American Journal of Physiology: Heart and Circulatory Physiology

SN - 0363-6135

IS - 5

ER -